奥拉帕利单药对比医生选择化疗治疗复发性卵巢癌的随机CLIO/BGOG-ov10试验
该随机试验将160例复发性卵巢癌患者(60例铂敏感,100例铂耐药)按2:1随机分为奥拉帕利单药组(107例)和医生选择化疗组(53例),总体客观缓解率两组相似(24.3%对28.3%),铂耐药组中位无进展生存期无显著差异(2.9个月对3.8个月,HR 1.11,95%CI 0.72-1.78,P=0.600)。
要点
- 总体客观缓解率奥拉帕利组24.3%(26/107)与化疗组28.3%(15/53)相似。
- 铂耐药组客观缓解率奥拉帕利17.9%(12/67)对化疗6.1%(2/33),P=0.134。
- 铂耐药组中位无进展生存期奥拉帕利2.9个月对化疗3.8个月,HR 1.11,未达统计学显著。
核心结论
- 奥拉帕利单药在复发性卵巢癌中总体缓解率与化疗相当。
- 在铂耐药卵巢癌中,奥拉帕利的客观缓解率和至首次后续治疗时间倾向于高于化疗。
- 在铂耐药且既往接受四线及以上治疗的患者中,奥拉帕利治疗似乎比化疗更有效。
研究设计与样本
- 随机、开放标签、2:1分配的CLIO/BGOG-ov10试验。
- 纳入可测量病灶且既往至少接受1线化疗的铂敏感或铂耐药卵巢癌患者。
- 奥拉帕利组给予300 mg片剂每日两次;化疗组由医生选择方案:铂敏感者为卡铂-聚乙二醇脂质体多柔比星或卡铂-吉西他滨,铂耐药者为聚乙二醇脂质体多柔比星、托泊替康、紫杉醇或吉西他滨。
- 共随机160例患者(铂敏感60例,铂耐药100例),奥拉帕利组107例,化疗组53例。
主要发现
- 总体客观缓解率奥拉帕利组24.3%(26/107)对化疗组28.3%(15/53),两组相似。
- 临床获益率(≥12周)奥拉帕利组54.2%(58/107)对化疗组56.6%(30/53),两组相似。
- 铂敏感组客观缓解率奥拉帕利35.0%(14/40)对化疗65.0%(13/20),P=0.053。
- 铂耐药组客观缓解率奥拉帕利17.9%(12/67)对化疗6.1%(2/33),P=0.134。
- 铂耐药且既往>4线治疗者客观缓解率奥拉帕利22.9%(8/35)对化疗0%(0/14)。
临床怎么用
- 作者认为奥拉帕利单药在复发性卵巢癌中总体缓解率与化疗相当。
- 作者指出在铂耐药卵巢癌中奥拉帕利的客观缓解率和至首次后续治疗时间倾向于高于化疗。
- 作者指出在铂耐药且既往接受四线及以上治疗的患者中,奥拉帕利治疗似乎比化疗更有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). METHODS: Patients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT.: for PSOC: Carboplatin-Pegylated-Liposomal-Doxorubicin (PLD) or Carboplatin-Gemcitabine; for PROC: PLD, Topotecan, Paclitaxel or Gemcitabine. RESULTS: 160 patients (60 with PSOC and 100 with PROC) were randomized 2:1 to OLA (n = 107) or CT (n = 53). Baseline characteristics were similar between both arms. Overall objective response rate (ORR) for OLA and CT were similar (24.3% (26/107) and 28.3% (15/53), respectively). Clinical benefit rate (≥ 12 weeks) was similar with 54.2% (58/107) and 56.6% (30/53), respectively. In PSOC, ORR was 35.0% (14/40) and 65.0% (13/20) for OLA and CT (p = 0.053); in PROC, ORR was 17.9% (12/67) and 6.1% (2/33) for OLA and CT (p = 0.134). ORR in heavily pretreated PROC (>4 prior lines) was 22.9% (8/35) with OLA versus 0% (0/14) for CT. ORR of 35.7% (5/14) and 13.2% (7/53) was observed in BRCA-mutated and -wildtype PROC cases, respectively. Median PFS in PROC was not significantly different with 2.9 months (95% CI 2.8-5.1 in the OLA group versus 3.8 months (95% CI 3.0-6.4) in the CT group (hazard ratio [HR] 1.11 [95% CI 0.72-1.78]; log-rank p = 0.600). CONCLUSION: OLA monotherapy showed overall an equal response rate in relapsed ovarian cancer compared with CT. In PROC, ORR and TFST tended to be higher with OLA than with CT. In heavily pretreated patients (four lines or more) with PROC disease, OLA treatment seemed to be more effective than CT.
引用
- Vanderstichele A, Loverix L, Busschaert P, et al. Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. Gynecol Oncol. 2022. PMID: 35177277. doi:10.1016/j.ygyno.2022.01.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。